<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-64957</identifier>
<setSpec>1575-0922</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:description xml:lang="en">Introduction and objectives: Dyslipidemia is frequently related to metabolic syndrome, which carries high cardiovascular risk. Statin therapy sometimes fails to achieve the recommended plasma lipid targets. The aim of this study was to evaluate the joint effect of ezetimibe and statin on lipid profile in dyslipidemic patients not achieving target values with statins alone and to determine the action of this combination on cardiovascular risk parameters, as well as its tolerability. Methods: We performed a descriptive prospective study in 50 consecutive hypercholesterolemic patients treated with statin alone and with poor metabolic control. Lipid profile and plasma concentrations of insulin, ferritin and homocysteine were evaluated after 3 months of combined treatment with ezetimibe. Results: We found a significant reduction in low density lipoproteins (p &lt; 0.001), a mean reduction in total cholesterol (p &lt; 0.001) and triglycerides (p = 0.002), as well as decreases in plasma concentrations of ferritin (p = 0,016), insulin (p = 0,010) and homocysteine (p &lt; 0.001) of 5%, 5% and 14%, respectively. There were no changes in either hepatic or muscular function. Conclusions: Combined treatment with ezetimibe and statin significantly improved lipid profile in poorly-controlled hypercholesterolemic patients treated with statin alone. There were no collateral effects on either hepatic or muscular parameters and there may be additional benefits on plasma levels of homocysteine, insulin and ferritin Objective: To assess the safety and efficacy of biphasic insulin aspart 30/70 in patients with type 2 diabetes mellitus (DM2). Material and methods: We performed an observational, multicenter, prospective study in 3,054 DM2 patients from primary care and specialized settings, treated with biphasic insulin aspart 30/70 (started within 15 days prior to inclusion). In all patients, the following information was available before starting insulin treatment: HbA1c levels, fasting plasma glucose (FPG), 4-point glucose profile (before and 90 minutes after breakfast and dinner) and number of hypoglycemic episodes/week. A total of 2,887 patients completed the study (26 ± 1 week). The variables evaluated were rate of adverse events (AE), number of hypoglycemic episodes/week, HbA1c, FPG and 4-point glucose profile. Results: At least one AE occurred in 10.7% of the patients (2.3% related to the study drug and 1.4% severe). There was a significant decrease (end of study vs baseline; p &lt; 0.0001 for all the comparisons) in HbA1c (7.3% and 8.9%, respectively), the mean number of minor (0.3/0.5) and major (0.02/0.07) hypoglycemic episodes/week, FPG (145/207 mg/dl) and postprandial glycemia (162/225 mg/dl). The improvement in metabolic control was achieved both in patients previously treated with oral antidiabetic drugs and in those treated with insulin. The number of hypoglycemic episodes decreased in patients previously treated with insulin. Conclusions: Treatment with biphasic insulin aspart 30/70 in patients with DM2 improves glycemic control, irrespective of previous treatment, with a low rate of AE and fewer hypoglycemic episodes in patients previously treated with insulin (AU)</dc:description>
<dc:creator>Zurro-Hernández, José</dc:creator>
<dc:creator>González-Sarmiento, Enrique</dc:creator>
<dc:creator>Fernández-Galante, Inmaculada</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Introducción y objetivos: La dislipemia se relaciona frecuentemente con el síndrome metabólico, proceso de elevado riesgo cardiovascular. En ocasiones, el tratamiento con estatinas no es suficiente para alcanzar las concentraciones plasmáticas de lípidos recomendadas. El objetivo del estudio fue evaluar el efecto de ezetimiba administrado con estatinas en el perfil lipídico de pacientes dislipémicos que no alcanzaron los objetivos deseables sólo con estatinas, así como valorar la acción sobre parámetros de riesgo cardiovascular y su tolerancia. Métodos: Estudio descriptivo, prospectivo, realizado en 50 pacientes hipercolesterolémicos consecutivos mal controlados sólo con estatinas, en los que se valora la mejoría del perfil lipídico y las concentraciones de insulina, ferritina y homocisteína plasmáticos tras tratamiento combinado con ezetimiba al cabo de 3 meses. Resultados: Se observó una disminución de las lipoproteínas de baja densidad (p &lt; 0,001), con una reducción media del colesterol total (p &lt; 0,001) y de los triglicéridos (p = 0,002), así como la de las concentraciones plasmáticas de ferritina (p = 0,016), insulina (p = 0,010) y homocisteína (p &lt; 0,001), con una reducción porcentual en las concentraciones del 5, el 5 y el 14%, respectivamente. No se objetivaron modificaciones en los parámetros de función hepática ni muscular. Conclusiones: La coadministración de ezetimiba y estatina mejoró, de forma marcada y significativa, el perfil lipídico en pacientes con hipercolesterolemia mal controlada con estatinas, sin efectos deletéreos en los parámetros hepáticos o musculares y es probable que pueda acompañarse de efectos beneficiosos adicionales en las concentraciones plasmáticas de homocisteína, insulina y ferritina Objective: To assess the safety and efficacy of biphasic insulin aspart 30/70 in patients with type 2 diabetes mellitus (DM2). Material and methods: We performed an observational, multicenter, prospective study in 3,054 DM2 patients from primary care and specialized settings, treated with biphasic insulin aspart 30/70 (started within 15 days prior to inclusion). In all patients, the following information was available before starting insulin treatment: HbA1c levels, fasting plasma glucose (FPG), 4-point glucose profile (before and 90 minutes after breakfast and dinner) and number of hypoglycemic episodes/week. A total of 2,887 patients completed the study (26 ± 1 week). The variables evaluated were rate of adverse events (AE), number of hypoglycemic episodes/week, HbA1c, FPG and 4-point glucose profile. Results: At least one AE occurred in 10.7% of the patients (2.3% related to the study drug and 1.4% severe). There was a significant decrease (end of study vs baseline; p &lt; 0.0001 for all the comparisons) in HbA1c (7.3% and 8.9%, respectively), the mean number of minor (0.3/0.5) and major (0.02/0.07) hypoglycemic episodes/week, FPG (145/207 mg/dl) and postprandial glycemia (162/225 mg/dl). The improvement in metabolic control was achieved both in patients previously treated with oral antidiabetic drugs and in those treated with insulin. The number of hypoglycemic episodes decreased in patients previously treated with insulin. Conclusions: Treatment with biphasic insulin aspart 30/70 in patients with DM2 improves glycemic control, irrespective of previous treatment, with a low rate of AE and fewer hypoglycemic episodes in patients previously treated with insulin (AU)</dc:description>
<dc:source>Endocrinol Nutr;55(4): 165-169, abr. 2008. ilus, tab</dc:source>
<dc:identifier>ibc-64957</dc:identifier>
<dc:subject>^d931^s22073</dc:subject>
<dc:subject>^d1166^s22054</dc:subject>
<dc:subject>^d28607</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d931^s22020</dc:subject>
<dc:type>article</dc:type>
<dc:date>200804</dc:date>
</metadata>
</record>
</ibecs-document>
